In the second part of our series from the 'Patient Experience: Empathy and Innovation' Digital Summit, we look at what COVID-19 can teach us about designing truly value-based healthcare.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh